Brian J. Long

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index4.6kcitations131works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(30), Cancer Immunotherapy and Biomarkers(25), Hippo pathway signaling and YAP/TAZ(22), interferon and immune responses(14), Melanoma and MAPK Pathways(10)

Publications131 total

Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies
Journal of Medicinal Chemistry·2026
Multiexpert dual-channel framework for robust urban traffic forecasting
2025
Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
Frontiers in Immunology·2025Open Access
Abstract 27: Orthotopic tumor models using luciferized patient-derived organoids for investigating EGFR-MAPK pathway inhibition in colorectal and pancreatic cancer
Cancer Research·2025
Abstract 22: Engineering KRAS-mutant-organoids from pancreatic ductal adenocarcinoma for advanced drug screening applications <i>in-vitro</i> and <i>in-vivo</i>
Cancer Research·2025
Abstract 2163: Inhibition of HIF2A increases efficacy of immune checkpoint blockade in renal cell carcinoma
Cancer Research·2025
Abstract 2193: Patient-derived colorectal microtumors predict response to anti-PD1 therapy
Cancer Research·2025
Searching potential GSK-3β inhibitors from marine sources using atomistic simulations
Molecular Diversity·2025
Abstract B002: HIF-2A inhibition in adaptive immunity against cancer growth
Cancer Immunology Research·2024
Figure S6 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Data from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Figure S1 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Figure S1 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Supplementary table 2 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Supplementary table 1 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Supplementary Methods from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Figure S3 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Figure S2 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Figure S3 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
Supplementary table 2 from Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Angela Brodie(13), Danijela Jelovac(10), Paul T. Kirschmeier(8), Dmitry N. Grigoryev(8), Angela Brodie(8), W. Robert Bishop(6), Ivo Nnane(6), Ahmed A. Samatar(5), Apinya Thiantanawat(5), A. Brodie(5), Qing Lü(5), Vincent C.O. Njar(5), Priya Dayananth(4), Alan Cooper(4), Donna Carr(4), Stuart Black(4), Gerald W. Shipps(4), Gongjie Liu(4), Stacey A. Taylor(4), Hugh Zhu(3)